Evaluating 68Ga-FAPI PET/CT for Thyroid Cancer with Lymph Node Metastases
The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
This study is testing a new type of imaging called 68Ga-FAPI PET/CT to see if it helps doctors better assess thyroid cancer in patients with lymph node spread before surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 16 Years to 80 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06730529 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 68Ga-FAPI PET/CT imaging in the preoperative assessment of thyroid cancer patients with lymph node metastases. Participants will be numbered and have their basic demographic and medical history recorded. Each participant will undergo a 68Ga-FAPI PET/CT scan prior to surgery, and the imaging results will be compared against histopathological findings to determine accuracy and value. The goal is to enhance preoperative evaluation methods for better surgical outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 16-80 with a clinical and pathological diagnosis of thyroid cancer that has spread to lymph nodes.
Not a fit: Patients with serious comorbidities or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of preoperative evaluations for thyroid cancer, leading to better treatment planning and outcomes.
How similar studies have performed: While the use of PET/CT imaging in cancer evaluation is established, the specific application of 68Ga-FAPI in thyroid cancer is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathological and clinical diagnosis of thyroid cancer with lymph node metastases. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. Aged 16-80 years old. Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction. 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person.
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jiajia Hu
- Email: jiajiahu@shsmu.edu.cn
- Phone: 13524945287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.